Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 405 IDR -0.35%
Market Cap: 65.9T IDR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one KLBF stock under the Base Case scenario is 1 924.83 IDR. Compared to the current market price of 1 405 IDR, Kalbe Farma Tbk PT is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KLBF Relative Value
Base Case
1 924.83 IDR
Undervaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2
P/S
P/S
Price to Sales
2
vs History
90
vs Industry
57
Median 3Y
2.5
Median 5Y
2.7
Industry
2.4
Forward
1.8
More Details
19.9
P/E
P/E
Price to Earnings
19.9
vs History
88
vs Industry
28
Median 3Y
24.7
Median 5Y
24
Industry
20.3
Forward
18.1
More Details
13.5
P/OCF
P/OCF
Price to OCF
13.5
vs History
90
vs Industry
36
Median 3Y
27.3
Median 5Y
20.5
Industry
15.6
More Details
18.8
P/FCFE
P/FCFE
Price to FCFE
18.8
vs History
90
vs Industry
24
Median 3Y
51.1
Median 5Y
37.5
Industry
23.1
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
90
vs Industry
31
Median 3Y
3.6
Median 5Y
3.7
Industry
2
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
90
vs Industry
60
Median 3Y
2.4
Median 5Y
2.5
Industry
2.5
Forward
1.7
More Details
4.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.8
vs History
88
vs Industry
48
Median 3Y
6.2
Median 5Y
6.1
Industry
4.8
More Details
14.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.8
vs History
87
vs Industry
28
Median 3Y
18.5
Median 5Y
17.3
Industry
12.5
Forward
11.3
More Details
14.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.8
vs History
87
vs Industry
32
Median 3Y
18.5
Median 5Y
17.3
Industry
15.7
Forward
13.2
More Details
12.6
EV/OCF
EV/OCF
Enterprise Value to OCF
12.6
vs History
90
vs Industry
38
Median 3Y
25.1
Median 5Y
19.6
Industry
14.1
More Details
17
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
17
vs History
90
vs Industry
27
Median 3Y
38.7
Median 5Y
34.1
Industry
17.6
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
90
vs Industry
33
Median 3Y
3.4
Median 5Y
3.6
Industry
1.8
More Details

Multiples Across Competitors

KLBF Competitors Multiples
Kalbe Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Kalbe Farma Tbk PT
IDX:KLBF
64.6T IDR 2 19.9 14.8 14.8
US
Eli Lilly and Co
NYSE:LLY
736.1B USD 15 66.3 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
378.4B USD 4.2 17.4 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.6 13 14.7
CH
Roche Holding AG
SIX:ROG
211.7B CHF 3.5 25.6 9.6 11.2
CH
Novartis AG
SIX:NOVN
179.9B CHF 4.1 17 10 13.5
UK
AstraZeneca PLC
LSE:AZN
162.9B GBP 3.9 27.9 130.6 197
US
Merck & Co Inc
NYSE:MRK
200B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.6B USD 2.1 16.4 7.2 10.1
P/E Multiple
Earnings Growth PEG
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/E: 24.6
19.9
10%
2
US
Eli Lilly and Co
NYSE:LLY
66.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.6
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.6
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBITDA: 395.4
14.8
12%
1.2
US
Eli Lilly and Co
NYSE:LLY
35.6
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
6%
1.6
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBIT: 1 698.6
14.8
9%
1.6
US
Eli Lilly and Co
NYSE:LLY
38.9
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.6
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.5
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
197
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
KLBF intrinsic value, competitors valuation, and company profile.
DCF Valuation
KLBF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KLBF stock valuation using valuation multiples.
Wall Street Estimates
KLBF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KLBF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.